Immuneering Corporation IMRX
3.38 USD -0.07 (-2.03%)
Regular-session close
3.33 -0.05 -1.48%
After hours · Nov 20, 7:37 PM ET
3.29 Day range 3.54
3.37 52-week range 8.33
- YTD
- -48.63%
- 1 year
- -51.65%
News
benzinga.com Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today presented new preclinical data demonstrating the…
globenewswire.com Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer - Atebimetinib has already reported compelling Phase 2 clinical data in first-line pancreatic cancer, is currently being evaluated in a Phase 3 trial in first-line pancreatic cancer, and will soon…
globenewswire.com Immuneering Presents Additional Data Demonstrating Atebimetinib's Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer - Atebimetinib in combination with chemotherapies has shown excellent results in Phase 2, including long survival and an outstanding tolerability profile in an all-comers population of first-line…
seekingalpha.com Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials Transcript Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials Transcriptbenzinga.com Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer - Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant…
benzinga.com Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients - Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a…
globenewswire.com Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer - Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant…
globenewswire.com Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients - Collaboration aligns with Immuneering's expanding strategy to provide a broad population of cancer patients with a wide set of treatment options - - Represents Immuneering's fourth agreement with a…
globenewswire.com Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors - Former TESARO Chief Commercial Officer and Nuvalent board member brings extensive experience in oncology product launches and commercial strategy - - Led commercialization of ZEJULA for ovarian…benzinga.com Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced compelling preclinical data…
globenewswire.com Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 - Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival…
globenewswire.com Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
globenewswire.com Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
globenewswire.com Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in…
globenewswire.com Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 - Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer -…
globenewswire.com Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in…
globenewswire.com Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer - Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -
globenewswire.com Immuneering to Present at the ESMO Congress 2026 NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
defenseworld.net Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX Squarepoint Ops LLC decreased its position in shares of Immuneering Corporation (NASDAQ: IMRX) by 74.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the…
globenewswire.com Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival - Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the…
globenewswire.com Immuneering to Participate in Upcoming Investor Conferences NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
globenewswire.com Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic…
247wallst.com Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most…
globenewswire.com Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on…
